Skip to main content


AAN 2019

medwireNews was at the AAN Annual Meeting 2019 in Philadelphia, Pennsylvania, USA, bringing you expert video interviews.

Expert interviews

09-05-2019 | Multiple sclerosis | Video

AAN 2019: Paediatric MS disability scoring system developed

Jonathan Santoro summarises their research evaluating disability distribution in paediatric-onset multiple sclerosis using a novel scoring model, and discusses the implications for the care of patients (4:31).

09-05-2019 | Motor neuron diseases | Video

AAN 2019: Risdiplam potential for type 2, 3 SMA demonstrated

Laurent Servais presents the safety and exploratory efficacy data from the SUNFISH study evaluating the SMN2 pre‐mRNA splicing modifier risdiplam in individuals who have type 2 or 3 spinal muscular atrophy (4.33).

08-05-2019 | Multiple sclerosis | Video

AAN 2019: Serum NfL levels linked to cognitive deficits in secondary progressive MS setting

Jens Kuhle discusses their analysis of data from the EXPAND trial indicating that blood neurofilament light chain levels could be a biomarker for cognitive impairment in patients with secondary progressive multiple sclerosis, and also outlines the knowledge gaps (4:16).

08-05-2019 | Motor neuron diseases | Video

AAN 2019: Promising early results for risdiplam in babies with type 1 SMA

Laurent Servais reports on part 1 of the FIREFISH trial of risdiplam in infants with type 1 spinal muscular atrophy showing improvements in various outcomes, including motor function and ventilation (3:55).

08-05-2019 | Parkinson's disease | Video

AAN 2019: LRRK2, GBA carriers exhibit subtle manifestations of Parkinson’s disease

Tatyana Simuni describes the clinical and imaging features of LRRK2 and GBA mutation carriers participating in the Parkinson's Progression Markers Initiative cohort (6:29).

07-05-2019 | Multiple sclerosis | Video

AAN 2019: Amyloid PET may predict cognitive decline in patients with MS

Jordi Matias-Guiu summarises the findings of their prospective study investigating the use of amyloid positron emission tomography to identify multiple sclerosis patients likely to experience cognitive impairment (3:10).

07-05-2019 | Multiple sclerosis | Video

AAN 2019: CHORDS sheds light on safety and effectiveness of ocrelizumab in real-world setting

Thomas Leist takes us through the 1-year interim analysis of the CHORDS study of ocrelizumab comprising multiple sclerosis patients drawn from community practice (2:04).

07-05-2019 | Multiple sclerosis | Video

AAN 2019: Research emphasizes need to use higher efficacy therapies in younger MS patients

Enrique Alvarez discusses their research demonstrating a difference in the efficacy of multiple sclerosis medications by age, and comments on the implications for clinical practice (5:04).

06-05-2019 | Multiple sclerosis | Video

AAN 2019: Cladribine benefit observed across all subgroups in ORACLE-MS study

Thomas Leist outlines a post-hoc analysis of the ORACLE-MS trial of individuals with a first demyelinating event showing that all subgroups appear to benefit from treatment with cladribine. He also discusses future directions of research (3:52).

02-05-2019 | Rheumatology | News | Article

Multifactorial nature of cognitive dysfunction highlighted in SLE

Poor attenuation of the default mode network regions of the brain may contribute to cognitive impairments in patients with systemic lupus erythematosus, say UK researchers.

07-02-2019 | Alzheimer's disease | News | Article

Early tau deposition findings support sex differences in AD risk

Researchers have found that clinically healthy women with high amyloid burden have elevated tau deposition compared with men.

31-01-2019 | Parkinson's disease | News | Article

Early levodopa treatment not justified in Parkinson’s disease

Levodopa does not modify Parkinson’s disease, show study findings suggesting there is no benefit to starting the drug early in the disease course.

24-01-2019 | Alzheimer's disease | News | Article

Frailty plays a key role in dementia risk

Frailty appears to modify the relationship between Alzheimer’s disease pathology and Alzheimer’s dementia, with increased levels making people more susceptible to clinical disease.

17-01-2019 | Multiple sclerosis | News | Article

Early aggressive treatment to delay conversion to secondary progressive MS

The findings from two studies published in JAMA show the benefits of initial disease-modifying therapy and nonmyeloablative haematopoietic stem cell transplantation in delaying conversion to secondary progressive multiple sclerosis.

10-01-2019 | Multiple sclerosis | News | Article

Rituximab shows disability benefits in patients with secondary progressive MS

Rituximab treatment may reduce and delay disability progression in patients with secondary progressive multiple sclerosis, show findings from a comprehensive real-world cohort study.

Twitter Icon Follow medwireNews

Click here
Image Credits